Regeneration Technologies, Inc.

Regeneration processes and sterilises allograft and xenograft implants to repair and promote the natural healing of human bone and other human tissues.

Regeneration Technologies, Inc. was founded in February 1998 as a spin-out of the University of Florida Tissue Bank, Inc. (UFTB, now called Southeast Tissue Alliance). In 2000, Regeneration Technologies went public and is traded on the NASDAQ exchange under the trading symbol RTIX.

With the acquisition of the Alabama Tissue Center, a division of the University of Alabama Health Services Foundation, the company entered the heart valve processing market. Since August 2005 Alabama Tissue Center was renamed as RTI - Cardiovascular. Currently 450 employees are working for Regeneration Technologies, Inc.

Brian K. Hutchison, Chairman, President and CEO
Thomas F. Rose, VP and CFO
Roger W. Rose, Executive Vice President
Bill Melendez, Vice President of Research and Development
Lennox K. Archibald, MD, FRCP, DTM&H, Medical Director

Brian K. Hutchison
Julianne M. Bowler
Phillip R. Chapman
Peter F. Gearen, M.D.
Michael J. Odrich
Gregory P. Rainey
David J. Simpson

Street Address:

11621 Research Circle
Alachua, FL 32615
USA

Postal Address:

P.O. Box 2650
Alachua, FL 32616-2650
USA

Phone:+1-386-418-8888
Fax: +1-386-418-0342

RTI’s lead product, BioCleanse®, is a tissue sterilisation process to eliminate bacteria, fungi, spores and viruses from the tissue. It is a validated, automated, pharmaceutical grade sterilisation process for musculoskeletal bone and soft tissue. In the first step, a vakuum/pressure process removes blood, lipids and marrow. In a second step, chemical sterilants thoroughly penetrates the tissue in order to eliminate pathogenic organisms including HIV, hepatitis B and C, bacteria, fungi and spores. The final step removes germicides, preserving biomechanical integrity and biocompatibility.

Allografts processed by RTI include the patented MD-Series™ threaded bone dowels, Cornerstone-SR™ blocks, Opteform® and Optefil™ allograft pastes, Osteofil/Regenafil™ injectable bone paste, FasLata™ fascia lata tissue, and cortical bone pins and interference screws. Xenograft processed by RTI includes the Sterling® Interference Screw ST, with distribution to begin in late 2005.

Regeneration Technologies Inc. owns a strong patent portfolio. A selection of patents are listed below. For comprehensive data please refer to the American Patent and Trademark Office or to the espacenet databases.